Suven Life Peer Comparison

NSE: SUVEN | BSE: 530239

₹258.85

₹-5.35 (-2.02%)

As on 30-Oct-2026IST

Market cap

₹7,293 Cr

Revenue (TTM)

₹9 Cr

P/E Ratio

P/B Ratio

13.1

Div. Yield

0 %

Edit

	Suven Life	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	7,293	35,440	25,276	17,311	13,028
Revenue (₹ Cr)	9	9,683	2,372	2,684	1,170
Net Profit (₹ Cr)	-352.44	1,018.97	497.77	669.74	279.64
Net Margin (%)	-1,187.94	10.47	20.72	24.24	22.94
RoE (%)	-80.77	21.30	28.49	19.79	13.92
Price to Earnings	--	35.04	50.78	25.85	46.13
Price-To-Book	13.10	6.78	12.51	4.77	6.28

Income Statement (₹ Cr)

	Suven Life	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	8.81	9,683.45	2,371.81	2,684.41	1,170.41
Total Income	29.67	9,730.84	2,402.61	2,763.43	1,218.73
Total Expenditure	375.07	7,739.53	1,608.91	1,761.70	766.14
EBITDA	-366.26	1,943.92	762.90	922.70	404.27
Depreciation	6.40	425.10	98.11	82.27	74.77
EBIT	-372.66	1,518.82	664.79	840.44	329.50
Interest	0.63	148.45	26.33	5.42	0.24
Other Income	20.85	47.39	30.80	79.02	48.32
Exceptional Items	0.00	-27.85	0.00	-25.66	-3.28
Profit before Tax	-352.44	1,389.91	669.26	888.39	374.31
Provision for Tax	0.00	370.94	171.48	218.65	94.68
Profit after Tax	-352.44	1,018.97	497.77	669.74	279.64

	Suven Life	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	591.40	4,950.03	1,874.47	3,631.29	2,075.76
Minority Interest	0.00	-7.58	0.00	0.00	3.07
Non-Current Liabilities	1.92	723.57	345.47	146.95	53.38
Current Liabilities	30.90	3,912.24	710.20	563.70	201.71
Total Liabilities	624.21	9,514.48	2,930.14	4,157.10	2,231.79

	Suven Life	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	59.44	3,392.16	1,290.62	1,454.42	980.16
Current Assets	546.71	5,612.10	1,483.13	2,864.85	1,290.68
Total Assets	624.21	9,514.48	2,930.14	4,157.10	2,231.79
Total Debt*	0.00	1,204.08	196.61	0.00	0.00
Net Current Assets	515.81	1,699.86	772.93	2,301.15	1,088.97
Contingent Liabilities	6.17	258.92	13.18	4.82	3.76

	Suven Life	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	-301.41	943.55	346.68	565.41	266.88
Cash Flow from Investing Activities	-462.11	-1,193.06	-423.73	-570.15	-142.72
Cash from Financing Activities	756.78	343.43	20.98	-64.34	-112.88
Net Cash Inflow / Outflow	-6.75	93.92	-56.08	-69.08	11.28

	Suven Life	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	-78.71	25.25	27.50	24.61	18.04
ROE (%)	-80.77	21.30	28.49	19.79	13.92
ROA (%)	-92.82	11.42	19.48	16.78	12.86
EBIT Margin (%)	-4,228.02	15.68	28.03	31.31	28.15
Net Margin (%)	-1,187.94	10.47	20.72	24.24	22.94
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Suven Life	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	17.25	18.36	78.33	8.19	4.02
EBIT Growth (%)	-94.41	30.43	303.07	24.77	-11.95
Net Profit Growth (%)	-91.31	32.39	182.61	26.27	-12.44
EPS Growth (%)	-70.96	36.68	277.72	29.79	-12.06
Book Value Growth (%)	299.38	11.36	22.95	18.43	11.27

	Suven Life	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	-17.87	34.32	50.78	25.07	45.73
Price / Book Value	13.10	6.78	12.51	4.77	6.28
Dividend Yield (%)	0.00	0.19	0.17	0.36	0.61
EV/EBITDA	-18.50	18.77	32.92	17.91	31.20
Market Cap (₹ Cr)	3,503.53	30,257.56	15,412.11	11,956.86	10,627.92

	Suven Life	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.00	0.05	0.09	0.00	0.00
Short term debt to equity ratio	--	0.16	--	--	--
Current Ratio	17.69	1.43	2.09	5.08	6.40
Quick Ratio	17.69	0.82	1.37	3.69	4.43
Interest Coverage	-554.90	10.36	26.41	165.03	1,593.82

	Suven Life	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	17.11	26.46	22.82	36.81	35.24
Asset Turnover	0.02	1.09	0.93	0.67	0.54
Receivable days	72.97	88.68	77.32	144.58	169.86
Inventory Days	8.71	84.11	80.83	96.67	97.92
Payable days	--	176.65	125.94	135.45	159.68
Cash Conversion Cycle	--	-3.86	32.22	105.80	108.11

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.